<DOC>
	<DOCNO>NCT00928304</DOCNO>
	<brief_summary>To determine sensitivity visual assessment BAY94-9172 PET image detect cerebral β-amyloid individual Down Syndrome ( DS ) specificity individual without DS . Given individual Down Syndrome develop β-amyloid pathology age 40 , clinical diagnosis Down Syndrome serve standard truth .</brief_summary>
	<brief_title>Phase II Study Florbetaben ( BAY94-9172 ) PET Imaging Detection/Exclusion Cerebral β-amyloid .</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Amyloidosis</mesh_term>
	<mesh_term>Down Syndrome</mesh_term>
	<criteria>Study participant individual DS healthy volunteer ( HVs ) . Main inclusion criterion individual without DS &gt; =21 &lt; = 40 year age MiniMental State Examination ( MMSE ) &gt; = 28 Clinical Dementia Rating ( CDR ) 0 Main inclusion criterion individual DS &gt; = 40 year age Main exclusion criterion group Unstable medical psychiatric condition , study specific screen procedure understand patient right withdraw study time</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Amyloid beta-protein</keyword>
	<keyword>Down Syndrome</keyword>
</DOC>